Bone Mineral Density in Antiretroviral Therapy-Naive HIV-1-Infected Young Adult -Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda

被引:5
|
作者
Matovu, Flavia Kiweewa [1 ,2 ]
Nabwana, Martin [1 ]
Kiwanuka, Noah [2 ]
Scholes, Delia [3 ]
Isingel, Esther [1 ]
Nolan, Monica L. [1 ]
Fowler, Mary G. [4 ]
Musoke, Philippa [1 ,2 ]
Pettifor, John M. [5 ]
Brown, Todd T. [4 ]
Beksinska, Mags E. [6 ]
机构
[1] Makerere Univ Johns Hopkins Univ MU JHU Res Colla, Kampala, Uganda
[2] Makerere Univ, Coll Hlth Sci, Kampala, Uganda
[3] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Univ Witwatersrand, SAMRC Wits Dev Pathways Hlth Res Unit, Fac Hlth Sci, Johannesburg, South Africa
[6] Univ Witwatersrand, Maternal Adolescent & Child Hlth Res Unit, Fac Hlth Sci, Johannesburg, South Africa
基金
美国国家卫生研究院;
关键词
ANTIRETROVIRAL THERAPY-NAiVE; BONE MINERAL DENSITY; DEPOT MEDROXYPROGESTERONE ACETATE; HUMAN IMMUNODEFICIENCY VIRUS; HIV-INFECTED PATIENTS; B LIGAND RANKL; RISK-FACTORS; OSTEOPOROSIS; DISEASE; PREVALENCE; OSTEOPENIA; FRACTURES; MASS; SECRETION;
D O I
10.1002/jbm4.10446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Most studies evaluating BMD in human immunodeficiency virus (HIV)-infected populations have focused on antiretroviral therapy (ART)-experienced patients. In this study, the association between HIV-1 and/or depot medroxyprogesterone acetate (DMPA) and BMD among untreated HIV-1-infected women in a resource-limited setting was assessed before long-term exposure to ART. The data were then compared with that of the 2005-2008 United States National Health and Nutrition Examination Survey data for non-Hispanic White and Black women. Women aged 18-35years, recruited from health facilities in Kampala, Uganda, were classified based on their combination of HIV-1 status and DMPA use: (i) HIV-1-infected current DMPA users, (ii) HIV-1-infected previous DMPA users, (iii) HIV-1-infected nonhormonal-contraceptive users, and (iv) HIV-uninfected nonhormonal-contraceptive users. All HIV-1-infected women reported being ART-naive at baseline. BMD was measured at the lumbar spine, total hip, and femoral neck using DXA. Multivariate linear regression was used to assess the association between HIV-1 and/or DMPA and BMD Z-scores. Baseline data were analyzed for 452 HIV-1-infected (220 nonhormonal users, and 177 current and 55 previous DMPA users) and 69 HIV-1-uninfected nonhormonal-contraceptive users. The mean age was 26.1years (SD, 4.2) with a median duration of DMPA use among current users of 24.0months [medians (interquartile range), 12-48]. A higher proportion of HIV-1-infected previous (12.7%) or current DMPA users (20.3%) and nonhormonal users (15.0%) had low BMD (Z-score <= -2 at any of the three sites) compared with age-matched HIV-1-uninfected women (2.9%). HIV-1 infection and DMPA use were independently associated with significantly lower mean BMD Z-scores at all sites, with the greatest difference being among HIV-1-infected current DMPA users (5.6%-8.0%) versus uninfected nonhormonal users. Compared with non-Hispanic White and Black women, the Ugandan local reference population had generally lower mean BMD at all sites. Newer treatment interventions are needed to mitigate BMD loss in HIV-1-infected women in resource-limited settings. (c) 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
引用
收藏
页数:10
相关论文
共 20 条
  • [1] Body Composition, Soluble Markers of Inflammation, and Bone Mineral Density in Antiretroviral Therapy-Naive HIV-1-Infected Individuals
    Brown, Todd T.
    Chen, Yun
    Currier, Judith S.
    Ribaudo, Heather J.
    Rothenberg, Jennifer
    Dube, Michael P.
    Murphy, Robert
    Stein, James H.
    McComsey, Grace A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 63 (03) : 323 - 330
  • [2] Prevalence and risk factors for low bone mineral density in antiretroviral therapy-naive HIV-infected young men
    Paccou, J.
    Viget, N.
    Drumez, E.
    Cortet, B.
    Robineau, O.
    MEDECINE ET MALADIES INFECTIEUSES, 2018, 48 (07): : 442 - 448
  • [3] Bone Mineral Density, Fracture, and Vitamin D in Adolescents and Young Women Using Depot Medroxyprogesterone Acetate
    Pitts, Sarah A. B.
    Feldman, Henry A.
    Dorale, Amanda
    Gordon, Catherine M.
    JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2012, 25 (01) : 23 - 26
  • [4] An exploratory study of depot-medroxyprogesterone acetate and bone mineral density in adolescent and young adult women with cerebral palsy
    Roden, R. Claire
    Noritz, Garey
    McKnight, Erin R.
    Bonny, Andrea E.
    CONTRACEPTION, 2020, 101 (04) : 273 - 275
  • [5] Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review
    de Carvalho, Erico Higino
    Gelenske, Thais
    Bandeira, Francisco
    Pessoa Militao de Albuquerque, Maria da Fatima
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2010, 54 (02) : 133 - 142
  • [6] Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia
    Assoumou, Lambert
    Katlama, Christine
    Viard, Jean-Paul
    Bentata, Michelle
    Simon, Anne
    Roux, Christian
    Kolta, Sami
    Costagliola, Dominique
    Rozenberg, Sylvie
    AIDS, 2013, 27 (15) : 2425 - 2430
  • [7] Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception
    Wanichsetakul, P
    Kamudhamas, A
    Watanaruangkovit, P
    Siripakarn, Y
    Visutakul, P
    CONTRACEPTION, 2002, 65 (06) : 407 - 410
  • [8] Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception
    Beksinska, Mags E.
    Kleinschmidt, Immo
    Smit, Jenni A.
    Farley, Timothy M. M.
    CONTRACEPTION, 2007, 75 (06) : 438 - 443
  • [9] Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years
    Busen, NH
    Britt, RB
    Rianon, N
    JOURNAL OF ADOLESCENT HEALTH, 2003, 32 (04) : 257 - 259
  • [10] Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART
    Rey, David
    Treger, Michele
    Sibilia, Jean
    Priester, Michele
    Bernard-Henry, Claudine
    Cheneau, Christine
    Javier, Rose-Marie
    INFECTIOUS DISEASES, 2015, 47 (02) : 88 - 95